Biotech Daily Market Report October 12, 2006
October 12th 2006 07:39
ASX DOWN, BIOTECHS UP:
PHYLOGICA UP 12.5%, CYGENICS DOWN 8%
PHYLOGICA UP 12.5%, CYGENICS DOWN 8%
THE MARKET
The Australian stock market fell 0.40 percent on Thursday October 12, 2006, with the All Ordinaries down 21.4 points to 5,223.9 points. Nineteen of the Biotech Daily Top 40 stocks were up, 11 stocks fell, eight traded unchanged and two were untraded. Fourteen of the Top 20 rose and four fell, while five of the Second 20 rose and seven fell.
Phylogica was best, up four cents or 12.5 percent to 36 cents on small volumes, but Metabolic climbed 5.5 cents or 9.73 percent to 62 cents with 1.9 million shares traded. Traded, followed by Pharmaxis up 13 cents or 5.14 percent to $2.66. Phosphagenics and Progen climbed more than four percent; Bionomics, Cellestis and Neuren were up more than three percent; Avexa, Biota and Chemgenex were up two percent or more; with Clinical Cell, Mesoblast, Peplin, Peptech and Proteome up by more than one percent.
Resmed had the biggest turnover falling 2.04 percent to $5.29 with 5.0 million shares changing hands.
Cygenics took the deepest dive, down three cents or 7.89 percent to 35 cents on modest volumes, followed by Living Cell, down 1.5 cents or 7.14 percent to 19.5 cents. Cogstate, Optiscan and Uscom fell more than six percent; Cochlear, CSL and Starpharma fell more than three percent; Biosignal and Prana were down more than two percent; with Portland and Psivida down more than one percent.
TODAY'S NEWS
* PHOSPHAGENICS PHASE I PROVES TRANSDERMAL INSULIN
* PEPLIN COMPLETES PHASE II SKIN CANCER TRIAL ENROLMENT
* SLOW ENROLMENTS DELAY HEARTWARE TRIALS
* INTERSUISSE ASIA PACIFIC LIFE SCIENCE FORUM
* INCITIVE APPOINTS RUSSELL BROWN COMPANY SECRETARY
To view these articles readers need to subscribe to Biotech Daily.
See details at www.biotechdaily.com.au
| 30 |
| Vote |
Add To: 
subscribe to this blog